-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
The company has been ranked among the top 20 Chinese pharmaceutical listed companies in terms of competitiveness.
Category:
Time：2019-10-29
Recently, the 2019 China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference—along with the Exhibition Celebrating the 70th Anniversary of the Founding of New China and Showcasing Achievements in the Pharmaceutical Industry—opened at Yanqi Lake in Beijing. At the conference, companies that have made outstanding contributions to the pharmaceutical industry were honored, and the "Top 20 Most Competitive Listed Pharmaceutical Companies in China" list was released. Shisi Pharmaceutical Group stood out from over 300 pharmaceutical companies and successfully made it onto this list, ranking 15th and earning widespread acclaim for its strength. In the concurrently released List of Outstanding Enterprises in the Pharmaceutical Industry Commemorating the 70th Anniversary of the Founding of New China, Shisi Pharmaceutical was awarded the title of "Benchmark Enterprise."
Recently, the 2019 China Pharmaceutical Entrepreneurs, Scientists, and Investors Conference—along with the Exhibition Celebrating the 70th Anniversary of the Founding of New China: Achievements in the Pharmaceutical Industry—was inaugurated at Yanqi Lake in Beijing. At the conference, companies that have made outstanding contributions to the pharmaceutical industry were recognized, and the "Top 20 Most Competitive Listed Pharmaceutical Companies in China" list was released. Shisi Pharmaceutical Group stood out from over 300 pharmaceutical companies and successfully made it onto this list, ranking 15th and earning widespread acclaim for its strength. In the concurrently released List of Outstanding Enterprises in the Pharmaceutical Industry Commemorating the 70th Anniversary of the Founding of New China, Shisi Pharmaceutical was honored with the title of "Benchmark Enterprise."
It is reported that since 2009, the “Top 20 Chinese Pharmaceutical Listed Companies Competition” has been held for 11 consecutive years. This competition has received high recognition from both the industry and capital markets, becoming an annual event that draws significant attention within the sector. The selection process is based on the theoretical framework of the ECIRM model, which encompasses five dimensions: industry dimension, management dimension, capital dimension, resource dimension, and manager dimension. The companies included in the evaluation must meet the following basic criteria: As of December 31, 2018, they must be pharmaceutical listed companies that have been listed on major domestic and overseas stock exchanges for more than one year; they must be registered in China or have their primary business operations based in China; their annual revenue must exceed 100 million yuan; and they must have a solid track record of good creditworthiness.
The competitiveness of pharmaceutical companies is primarily reflected in two key areas: R&D innovation and marketing excellence. The Group has established a National Enterprise Technology Center, a Joint National-Local Engineering Laboratory for Quality Control of Chemical Injection Products, an Academician Workstation of the Chinese Academy of Engineering, a Research Workstation for International Nobel Laureates, an Engineering Research Center for Large-Volume Injection Systems, and an Engineering Research Center for Injection Drug Delivery Systems. Relying on these high-level innovation platforms, the Group has successively developed and launched a number of formulation products with strong market potential, including Abidol Hydrochloride Capsules, Moxifloxacin Injection, Sodium Acetate Ringer’s Injection, Lactate Gatifloxacin Glucose (Sodium Chloride) Injection, Lactate Levofloxacin Injection, and Ambroxol Hydrochloride Glucose Injection.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license